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Homeobox A9 (HOXA9) is a homeodomain-containing transcrip-
tion factor that plays a key role in hematopoietic stem cell expan-
sion and is commonly deregulated in human acute leukemias. A
variety of upstream genetic alterations in acute myeloid leukemia
(AML) lead to overexpression of HOXA9, almost always in associ-
ation with overexpression of its cofactor meis homeobox 1 (MEIS1) .
A wide range of data suggests that HOXA9 and MEIS1 play a syn-
ergistic causative role in AML, although the molecular mechanisms
leading to transformation by HOXA9 and MEIS1 remain elusive. In
this study, we identify CCAAT/enhancer binding protein alpha (C/
EBPα) as a critical collaborator required for Hoxa9/Meis1-mediated
leukemogenesis. We show that C/EBPα is required for the prolif-
eration of Hoxa9/Meis1-transformed cells in culture and that loss
of C/EBPα greatly improves survival in both primary and secondary
murine models of Hoxa9/Meis1-induced leukemia. Over 50% of
Hoxa9 genome-wide binding sites are cobound by C/EBPα, which
coregulates a number of downstream target genes involved in the
regulation of cell proliferation and differentiation. Finally, we
show that Hoxa9 represses the locus of the cyclin-dependent ki-
nase inhibitors Cdkn2a/b in concert with C/EBPα to overcome
a block in G1 cell cycle progression. Together, our results suggest
a previously unidentified role for C/EBPα in maintaining the pro-
liferation required for Hoxa9/Meis1-mediated leukemogenesis.
enhancer | gene regulation
Homeobox A9 (HOXA9) is a member of the highly conservedHOX protein family of transcription factors, which play key
roles in both development and hematopoiesis (1, 2). HOXA9 is
most highly expressed in long-term hematopoietic stem cells
(HSCs) and early progenitors, where it promotes cellular pro-
liferation and is subsequently down-regulated during differenti-
ation (3). Nearly one-half of acute myeloid leukemia (AML)
cases show up-regulation of HOXA9, which correlates strongly
with poor prognosis (4–8) (Fig. S1). In most cases, up-regulation
of HOXA9 is accompanied by up-regulation of its cofactorMEIS1,
which colocalizes with HOXA9 at enhancers (9, 10). Although
overexpression of HOXA9 alone is sufficient for transformation
of HSCs in culture, coexpression with MEIS1 increases trans-
formation efficiency and results in rapidly fatal leukemias in
transplanted animals (11).
A variety of upstream genetic alterations, including mixed-
lineage leukemia (MLL) translocations, NPM1 mutations, NUP98
translocations, and CDX2 overexpression, lead to HOXA9 up-
regulation in AML; however, the mechanisms through which
high levels of HOXA9 contribute to leukemic transformation
are not known (12–16). It has been suggested that lineage-
specific “collaborator” proteins bind at relevant loci along with
HOXA9 and its cofactors, PBX and MEIS proteins, to confer
both site specificity and transcriptional activity of the HOXA9
complex (17). Recently, our group identified a number of po-
tential Hoxa9 collaborators by characterizing the genome-wide
binding sites of Hoxa9 and Meis1 in a murine myeloblastic cell
line and by identifying proteins that interact with the Hoxa9 com-
plex (9). One of these putative collaborators is CCAAT/enhancer
binding protein alpha (C/EBPα), which coimmunoprecipitates
with Hoxa9. In addition, C/EBP recognition motifs are enriched
at Hoxa9 binding sites.
C/EBPα is a basic leucine-zipper transcription factor that plays
a critical role in lineage commitment during hematopoietic dif-
ferentiation (18). Whereas Cebpa−/− mice show complete loss of
the granulocytic compartment, recent work shows that loss of
C/EBPα in adult HSCs leads to both an increase in the number
of functional HSCs and an increase in their proliferative and
repopulating capacity (19, 20). Conversely, CEBPA overexpression
can promote transdifferentiation of a variety of fibroblastic cells to
the myeloid lineage and can induce monocytic differentiation in
MLL-fusion protein-mediated leukemias (21, 22).
Although C/EBPα binds directly to target gene promoters,
increasing evidence suggests that it also regulates gene expres-
sion through binding at promoter distal regulatory elements. For
example, C/EBPα has been reported to colocalize with Pu.1,
another critical regulator of hematopoiesis, at myeloid-specific
enhancers, where it acts to establish areas of chromatin acces-
sibility and facilitate the recruitment of signal-dependent tran-
scription factors (23). The ability of CEBPA to act as a pioneer
transcription factor at enhancers suggests that it may play a
similar role in HOXA9-driven leukemogenesis.
To test this hypothesis, we used models allowing for condi-
tional deletion of Cebpa in Hoxa9-transformed cells. We found
that C/EBPα is critical for maintaining cellular proliferation in
vitro and is a significant contributor to the severity of Hoxa9-
mediated leukemia in vivo. Using genome-wide analysis, we
found that C/EBPα colocalizes with Hoxa9 at promoter distal
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enhancers, resulting in both target gene activation and re-
pression. Finally, we identified the cyclin-dependent kinase
inhibitors Cdkn2a/b as critical targets of the Hoxa9–C/EBPα
complex, whose repression likely contributes to the aberrant
proliferation required for Hoxa9-mediated leukemogenesis.
Results
C/EBPα Is Required for Hoxa9/Meis1-Mediated Transformation. We
previously identified the lineage-specific transcription factor
C/EBPα as a member of the myeloid Hoxa9 complex (9). To de-
termine if C/EBPα is required for transformation by Hoxa9 and
Meis1, we generated cell lines that allow for conditional deletion
of Cebpa by retrovirally transducing bone marrow from Cebpaf/f;
CreERT+/− mice with Hoxa9/Meis1-GFP (Fig. 1A). We also
generated control cell lines from WT;CreERT+/− mice to control
for the effects of tamoxifen (OHT) treatment and Cre-mediated
toxicity. Continuous treatment of the Hoxa9/Meis1-transformed
Cebpaf/f;CreERT+/− (C/EBPα HM) cells with 4-hydroxytamoxifen
(4OHT) leads to near complete loss of C/EBPα over the course of
8 d (Fig. 1B). Loss of C/EBPα leads to a dramatic decrease in cellular
proliferation, whereas Cre induction in Hoxa9/Meis1-transformed
WT;CreERT+/− (WT HM) cells has no effect (Fig. 1 C and D).
Our previously published work using a Hoxa9-estrogen receptor
tag (ER)/Meis1 conditional cell line established that loss of Hoxa9
leads to a reduction in cellular proliferation, which is accompanied
by differentiation of the cells into macrophages and induction of
apoptosis (9). Although loss of C/EBPα also leads to a decrease in
cellular proliferation, we did not observe terminal differentiation
of these cells or induction of apoptosis (Fig. 1 E–H). Loss of C/
EBPα leads to the accumulation of cytoplasmic vacuoles at day
8 (Fig. 1E); however, this morphology did not progress with
continued treatment of cells for 15 d. No changes in cellular
morphology were observed in the WT HM cells under the same
treatment conditions (Fig. 1F). Analysis of cell surface marker
expression after loss of C/EBPα shows an increase in the im-
mature cell surface marker c-Kit and either stable or decre-
asing expression in the myeloid surface markers CD11b, Gr1,
F4/80, and Ly6C (Fig. 1G and Fig. S2). This phenotype persists
across a 15-d time course, whereas no changes were seen in the
WT HM control cells (Fig. 1G). These results are consistent
with the known importance of C/EBPα in promoting myeloid
differentiation, whereby cells lacking C/EBPα cannot initiate
the full myeloid differentiation program (18). Furthermore, loss of
C/EBPα does not lead to up-regulation of C/EBPβ and C/EBPe,
which are also important mediators of myeloid differentiation
(Fig. S3). We also tested whether loss of C/EBPα leads to induction
of apoptosis by flow cytometry. No significant increase of apoptosis
was seen after loss of C/EBPα compared with WT HM controls
(Fig. 1H). Thus, loss of C/EBPα in Hoxa9/Meis1-transformed cells
leads to a decrease in cellular proliferation in the absence of dif-
ferentiation or apoptosis.
Loss of C/EBPα Impairs Hoxa9-Mediated Leukemogenesis. Given the
importance of C/EBPα in maintaining rapid proliferation of
Hoxa9/Meis1-transformed cells, we next examined if C/EBPα
is required for Hoxa9/Meis1-leukemogenesis in vivo. We trans-
planted freshly transduced C/EBPα HM or WT HM cells into
lethally irradiated C57B6 mice. After 2 wk, the mice were treated
with biweekly injections of OHT to induce deletion of Cebpa in
the transplanted cells.
Loss of Cebpa significantly improved survival of the C/EBPα
HM-transplanted mice [n = 10(veh), 12(OHT); P < 0.0001],
whereas there was no survival difference seen in the vehicle- or
OHT-treated WT HM cohort [n = 10(veh), 14(OHT); P =
0.4324] (Fig. 2 A and B). Vehicle-treated mice from the C/EBPα
HM cohort, as well as all mice in the WT HM groups, developed
myeloblastic leukemia in an average of 40 d showing extensive
liver, spleen, and peripheral blood infiltration. Conversely,
C/EBPα HM mice treated with OHT developed leukemia in
an average of 60 d, also with infiltration of the liver and spleen in
late stages (Fig. 2C). This delay in leukemia is even more impres-
sive given that Cebpa−/− bone marrow is reported to have enhanced
repopulating activity and faster proliferation than WT cells (19).
Examination of C/EBPα levels in the bone marrow at the time
of death indicates that there is strong selective pressure for
maintaining high levels of C/EBPα in Hoxa9/Meis1-transformed
leukemias. One C/EBPαHMOHT-treated mouse died early and
showed complete loss of Cebpa expression, although this mouse
presented with a lower blast count and a more mature phenotype
than a C/EBPα HM vehicle-treated mouse that died on the same
day (day 35; “early”) (Fig. 2 C–E). On the other hand, the
remainder of the C/EBPα HM OHT-treated cohort that suc-
cumbed to leukemia at later time points showed recovery of
Cebpa expression and a phenotype similar to vehicle-treated
mice (day 60; “late”) through outgrowth of clones that had es-
caped Cre-mediated deletion (Fig. 2 C–E and Fig. S4). This
selective pressure for the presence of C/EBPα can also be seen in
cell culture, because cells eventually regain C/EBPα expression in
Fig. 1. C/EBPα is required for Hoxa9/Meis1-mediated transformation. (A)
Schematic of cell line generation and Cebpa-targeted allele. 5-FU, 5-
flurouracil. (B) C/EBPα HM andWT HM cells were treated for an 8-d time course
with 5 nM 4OHT or EtOH, and protein levels in the C/EBPα HM cells were
assessed using Western blotting. Cellular proliferation of both C/EBPα HM
(C) and WT HM (D) cells was determined by cell counting; data represent
mean ± SD of two independent experiments. Cell morphology of C/EBPα HM
(E) and WT HM (F) cells was assessed after 8 d. (Scale bars: 50 μm.) (G) Surface
expression of c-Kit, CD11b, and Gr1 at days 4 and 8 in C/EBPα HM cells (Left
and Center) and WT HM cells (Right) after continuous treatment with 4OHT
(red) or EtOH (blue). (H) Annexin V and DAPI staining for apoptotic cells at
day 8 of treatment with 4OHT or EtOH. Black numbers in the lower right
corner represent the mean number of apoptotic cells (AnnexinV+/DAPI−)
from four independent experiments. Mean ± SD values are as follows: C/EBPα
HM EtOH, 4.56 ± 3.62; C/EBPα HM 4OHT, 4.54 ± 1.23; WT EtOH, 5.74 ± 5.31,
and WT 4OHT, 5.38 ± 3.75. Flow cytometry plots from one representative
experiment are shown.
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the absence of 4OHT treatment despite genomic deletion of Cebpa
and loss of protein levels after 1 wk of 4OHT treatment (Fig. 2F).
The C/EBPα HM OHT-treated mouse that succumbed to leuke-
mia in the absence of C/EBPαmay be explained by the acquisition
of cooperating mutations or activation of compensatory
pathways to escape the requirement for C/EBPα expression.
We also examined the role of C/EBPα in secondary Hoxa9/
Meis1-induced leukemias. Spleen cells harvested from a C/EBPα
HM vehicle-treated primary leukemia mouse were injected into
the tail vein of sublethally irradiated C57B6 mice to establish
secondary leukemias, and the mice were then treated with OHT
to induce Cebpa excision. Loss of C/EBPα led to prolonged
survival of the mice with secondary leukemia [n = 9(veh),
7(OHT); P < 0.0001] (Fig. 2G). OHT-treated mice that were
killed as controls alongside leukemic vehicle-treated mice sh-
owed significantly reduced C/EBPα levels and tissue infiltra-
tion compared with the vehicle-treated mice, confirming the
efficacy of the OHT treatment (Fig. 2 H and I). Conversely, OHT-
treated mice that eventually succumbed to leukemia regained
high C/EBPα levels and showed liver infiltration similar to
vehicle-treated mice, again displaying strong selective pres-
sure for Cebpa reexpression (Fig. 2 H and I). Taken together,
these results show that C/EBPα is required for Hoxa9/Meis1-
mediated leukemogenesis.
Given these findings, we analyzed the relationship between
CEBPA and HOXA9 expression in a cohort of 344 human acute
leukemias [data reanalyzed from a study by Figueroa et al. (24)].
Although there was no significant correlation between the
expression level of CEBPA and HOXA9, this cohort included
leukemias with single and biallelic mutations in CEBPA, re-
sulting in both loss of function and dominant negative activi-
ties of the protein. Interestingly, when we analyzed expression of
HOXA9 relative to CEBPA mutational status, we found that
leukemias with at least one WT copy of CEBPA express high
levels of HOXA9, whereas cases with biallelic mutations of
CEBPA are associated with much lower levels of HOXA9
(Fig. 2J). These data provide further support for a require-
ment for WT CEBPA in human leukemias with high levels of
HOXA9 expression.
C/EBPα Colocalizes with Hoxa9 at Promoter Distal Enhancers. We
sought to establish a molecular mechanism for the functional
interplay between Hoxa9 and C/EBPα in leukemogenesis. Given
that Hoxa9 and C/EBPα physically interact and that the C/EBP
motif is enriched at Hoxa9 binding sites (9), we next determined
if C/EBPα cobinds with Hoxa9 on a genome-wide level. We
performed ChIP-sequencing (ChIP-seq) for Hoxa9 and C/EBPα in
a mouse myeloblastic cell line transformed with HA-Hoxa9-ER
Fig. 2. Loss of C/EBPα impairs Hoxa9-mediated
leukemogenesis. Survival curves for mice transpla-
nted with C/EBPα HM cells [A; n = 10(veh), 12(OHT);
P < 0.0001 by log rank] or WT HM cells [B; n =
10(veh), 14(OHT); P = 0.4324 by log rank]. The
treatment period with OHT (red) or vehicle (blue) is
indicated by the arrow below the graphs. (C) Tissue
histology of liver and bone, and bone marrow (BM)
cytospins for C/EBPα HM vehicle- and OHT-treated
mice that died before 40 d (Left and Center;
“early”) and an OHT-treated mouse that died at
60 d posttransplantation (Right; “late”). (Scale bars:
50 μm.) (D and E) RT-PCR expression of Cebpa and
Western blot analysis of C/EBPα protein levels cor-
responding to samples shown in C (mean ± SD). veh,
vehicle. (F) C/EBPα protein levels in cells treated
with 4OHT for 6 d and subsequently maintained in
the absence of 4OHT for an additional 10 d. The
rightmost lane (16E) corresponds to cells treated
continuously with EtOH for 16 d. (G) Survival curve
of mice transplanted with primary leukemic spleen
cells from a C/EBPα HM vehicle-treated mouse [n =
9(veh), 7(OHT); P < 0.0001 by log rank]. The treat-
ment period with OHT (red) or vehicle (blue) is in-
dicated by the arrow below the graph. (H) C/EBPα
protein levels in vehicle-treated leukemic mice (Left)
compared with OHT-treated mice preleukemic con-
trols (Center) and leukemic OHT-treated mice
(Right). (I) Liver histology of leukemic vehicle- and
preleukemic OHT-treated mice at 20 d. (Scale bars:
50 μm.) (J) HOXA9 expression level in a cohort of
patients with AML subdivided by CEBPA mutation
status (n = 344) ****P < 0.0005; **P < 0.005; ns, not
sigificant.
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and Flag-Meis1 (HerM). Because there are currently no antibodies
against Hoxa9 suitable for ChIP-seq, we used an HA antibody to
immunoprecipitate Hoxa9. We identified 6,535 peaks that are
bound by Hoxa9 and 26,187 peaks that are bound by C/EBPα, the
majority of which occur at promoter distal regions (Fig. 3A). No-
tably, a remarkable proportion (54%) of Hoxa9 binding sites are
cobound by C/EBPα (P < 0.001) (Fig. 3B). C/EBPα does not
appear to be absolutely required for Hoxa9 binding, however,
because cases of Hoxa9 binding sites with very low levels of C/
EBPα can be found even in the vicinity of strong cobound peaks
(Fig. 3C, Center and Right). To validate our ChIP-seq results,
multiple sites of each class of Hoxa9-bound enhancer were
confirmed using ChIP-quantitative PCR (Fig. 3D).
Finally, we examined the biological pathways enriched for pu-
tative targets of Hoxa9–C/EBPα-cobound enhancers. Sites cobound
by Hoxa9 and C/EBPα showed an enrichment for genes critical
for hematopoietic pathways, including the regulation of mye-
loid differentiation, regulation of the inflammatory response,
and regulation of cytokine production (Fig. S5). In addition,
cobound sites showed enrichment for pathways involved in
signal transduction, including the regulation of protein kinase
activity, MAP kinase activity, and serine/threonine kinase ac-
tivity. Collectively, these results suggest that C/EBPα func-
tionally interacts with Hoxa9 at enhancers to facilitate Hoxa9/Meis1-
mediated transformation.
C/EBPα and Hoxa9 Coregulate Expression of Cdkn2a/b. Given the
requirement for C/EBPα in Hoxa9/Meis1-mediated leukemic
transformation and the colocalization of C/EBPα with Hoxa9 at
enhancers in transformed cells, we next sought to identify target
genes potentially important for leukemogenesis. Using the
C/EBPα HM and HerM cells, we performed RNA-sequencing
(RNA-seq) at 72 h after loss of C/EBPα or Hoxa9. We identified
31 genes that were coactivated more than 1.5-fold by Hoxa9 and
C/EBPα, including Adam17, Igf2r, Il2ra, and Cpe (Table S1). In
addition, 45 genes were corepressed more than 1.5-fold, including
Gata2, Gfi1b, Prkca, and Cdkn2b (Table S2).
Interestingly, a number of genes were antagonistically regu-
lated by the two proteins, including the known C/EBPα target
Sox4, suggesting a competitive mechanism between C/EBPα and
Hoxa9 at some targets.
Two genes that were significantly repressed by both Hoxa9 and
C/EBP were Cdkn2a/b (INK4a/b). Cdkn2a/b are critical regu-
lators of HSC self-renewal, apoptosis, and oncogene-induced
senescence whose expression leads to a block in the cell cycle at
the G1 phase (25). In addition, Cdkn2a/b are commonly deleted
in acute lymphoid leukemias (26–28). Our ChIP-seq studies
identified a Hoxa9–C/EBPα-cobound site in an intergenic region
∼50 kb downstream of the Cdkn2a/b locus (Fig. 4A). Loss of
either C/EBPα or Hoxa9 binding at this locus (Fig. 4 B and C)
results in a corresponding increase in Cdkn2a/b expression (Fig.
4 D and E). In addition, loss of either C/EBPα or Hoxa9 leads to
only a slight reduction in the binding of the other protein, sug-
gesting that the cobinding of both proteins is necessary for re-
pression of the Cdkn2a/b locus (Fig. 4 B and C). Cell cycle
analysis performed on C/EBPα HM and HerM cells showed that
both loss of C/EBPα and loss of Hoxa9 in Hoxa9/Meis1-trans-
formed cells leads to G1 cell cycle blockade (Fig. 4 F and G).
These data suggest that corepression of the Cdkn2a/b locus by
C/EBPα and Hoxa9 contributes to the rapid proliferation induced
with Hoxa9-mediated transformation. Indeed, overexpression of
CDKN2A or CDKN2B in cells transformed by Hoxa9/Meis1 leads
to a decrease in proliferation relative to control cells transduced
with an empty vector (Fig. 4H).
Discussion
Although a variety of upstream genetic alterations in AML are
known to work through increased expression of HOXA9, the
downstream mechanisms through which high levels of HOXA9
mediate transformation are yet to be fully elucidated. In this
study, we identify C/EBPα as a critical collaborator protein of
Hoxa9 in myeloid leukemia. Our work shows that C/EBPα is
required for the rapid proliferation of Hoxa9/Meis1-transformed
cells in culture and for aggressive disease in primary and sec-
ondary murine models of Hoxa9/Meis1-induced leukemia. In this
context, it is noteworthy that human AMLs with high HOXA9
expression almost always retain one WT copy of CEBPA. Taken
together with the observation that null mutations of CEBPA are
almost never seen in AML, our data suggest that some residual
function of CEBPA is required for transformation (29). Al-
though these findings are surprising, given that high levels of
CEBPA have been shown to promote myeloid differentiation
(22), it is most likely that a moderate level of CEBPA is required
for HOXA9-mediated AML.
The requirement for CEBPA in AML may be specific to
leukemias with high levels of HOXA9. Recent work shows that
C/EBPα is required for the initiation of leukemias transformed
by MLL-ENL, a fusion protein that directly up-regulates HOXA9
expression (30, 31). Conversely, C/EBPα was shown to be dis-
pensable for E2A-HLF–mediated transformation, which has
undetectable levels of HOXA9 (31). This same study also found
that C/EBPα is not required for the maintenance of MLL-ENL–
induced leukemias. Taken together with our finding that C/EBPα
is required for the maintenance of Hoxa9-mediated transfor-
mation, these data suggest that MLL-ENL activates alternative
pathways to compensate for changes in Hoxa9 target gene
Fig. 3. C/EBPα colocalizes with Hoxa9 at promoter distal enhancers. (A)
Peak number and distribution of Hoxa9 and C/EBPα ChIP-seq in a Hoxa9/
Meis1-transformed cell line (“Other” category contains 5′/3′ UTR and exons).
Tx, transcription. (B) Peak overlap between Hoxa9 and C/EBPα ChIP-seq. (C)
Representative Hoxa9 (HA)/C/EBPα-cobound loci. Bars indicate location of
quantitative PCR (qPCR) primer pairs. (D) Independent ChIP-qPCR validation
of ChIP-seq data for Hoxa9 (Upper) and C/EBPα (Lower) binding at Hoxa9–
C/EBPα-cobound sites, Hoxa9 only, and nonbinding controls; bars indicate
mean ± SD of at least two independent experiments. Btla, B and T lymphocyte
associated; Klf5, Kruppel-like factor 5; Irf2, interferon regulatory factor 2.
9902 | www.pnas.org/cgi/doi/10.1073/pnas.1402238111 Collins et al.
regulation after loss of C/EBPα. Further characterization of the
downstream gene expression changes after loss of C/EBPα in
MLL-rearranged leukemias and other HOXA9-high leukemias,
especially in comparison to leukemias with low expression of
HOXA9, will help elucidate these alternative pathways.
Given that our work implicates a requirement for WT CEBPA
in the development of leukemia with a high level of HOXA9, it is
also interesting to speculate how mutant forms of CEBPA in AML
may functionally interact with HOXA9. About 10% of AMLs carry
mutations in CEBPA, two-thirds of which are biallelic mutations,
where one allele carries a mutation in the C-terminal DNA binding
domain and the other allele carries an N-terminal mutation that
leads to transcription of the short p30 isoform (29, 32, 33). These
mutations affect not only the binding and localization of CEBPA
but also the recruitment of coactivator and corepressor complexes
to CEBPA-bound loci (29, 34). In these cases, expression of
HOXA9 is very low, suggesting oncogene incompatibility between
high expression of HOXA9 and biallelic mutations of CEBPA. In
addition, the genetic signature of CEBPA mutant leukemias is
distinct from that of MLL-rearranged and other CEBPA WT
leukemias (35). Conversely, our work shows that single mutant
cases of CEBPA do occur in the presence of high levels of
HOXA9, potentially affecting target gene regulation. Further
study on the effect of various mutant forms of CEBPA on regula-
tion of HOXA9 target genes could provide valuable insight into
mechanisms of transformation in these cases.
In addition to uncovering an unexpected requirement of
C/EBPα in Hoxa9-mediated leukemogenesis, our work implicates
C/EBPα in the control of cell cycle and senescence in cells trans-
formed by Hoxa9/Meis1. Recent work has shown that Hoxa9
inhibits Cdkn2a expression in Bmi1−/−MLL-AF9 cells, allowing
for escape of the oncogene-induced senescence that is seen in
Bmi1−/− cells transformed with other oncogenes (36). Although
Hoxa9 was found to suppress Cdkn2a expression through direct
binding at the promoter, Smith et al. (36) suggest that other
non-HOX proteins may be involved in achieving full repression
of this locus. Our work implicates C/EBPα as a cofactor aiding
in Hoxa9 repression of both Cdkn2a and Cdkn2b, which is
potentially mediated through looping of the downstream Hoxa9–
C/EBPα-cobound site to the promoters. The silencing of both
CDKN2A/B through deletion or promoter methylation is known
to play critical roles in AML; thus, repression of this locus may
also be central to HOXA9/MEIS-mediated leukemogenesis
(26–28). Derepression of Cdkn2a/b may contribute to the G1
cell cycle blockade and decreased proliferation that occurs in
the absence of C/EBPα, although overexpression of CDKN2A
or CDKN2B in cells transformed by Hoxa9/Meis1 does not fully
recapitulate this phenotype. Therefore, it remains possible that
additional Hoxa9–C/EBPα-regulated target genes, in concert
with Cdkn2a/b, are critical to maintaining rapid proliferation in
cells transformed by Hoxa9/Meis1. Additional experiments are
required to identify these factors and their relationship with
Cdkn2a/b repression in promoting leukemogenesis downstream
of Hoxa9 and C/EBPα.
Finally, although C/EBPα is required for Hoxa9-mediated leu-
kemogenesis at essential coregulated targets, such as Cdkn2a/b,
we also suggest that high levels of Hoxa9 may antagonize C/EBPα
at genes associated with myeloid differentiation. Consistent with
this idea, we find that Hoxa9 and C/EBPα have antagonistic
effects on Sox4, which is reported to be a direct target of C/EBPα
and whose repression is required for normal hematopoietic dif-
ferentiation (35). Additional study of antagonistically regulated
HOXA9/CEBPA target genes may provide further insight into the
mechanisms through which high levels of HOXA9 expression lead
to transformation in AML.
Materials and Methods
Cell Lines. Lineage-depleted bone marrow from Cebpaf/f;CreERT+/−, WT;
CreERT+/−, or WT mice was retrovirally transduced with MIGR1-HA-Hoxa9 or
MIGR1-HA-Hoxa9-ER and MIGR1-Flag-Meis1 [plasmids previously described
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by Huang et al. (9)]. The detailed protocol and culture conditions are pro-
vided in SI Materials and Methods.
Cellular Assays. For loss of C/EBPα studies, cells were treated continuously
with ethanol (EtOH) or 5 nM 4OHT (H7904; Sigma). For the 4OHT withdrawal
experiment, after 1 wk of continuous culture in EtOH or 5 nM 4OHT, cells
were washed once with culture media and continued in culture with EtOH
only. For loss of Hoxa9 studies, cells were washed three times with culture
media and then maintained in either EtOH or 100 nM 4OHT. Detailed in-
formation on proliferation, morphology, Western blotting, RNA extraction,
and cDNA generation is provided in SI Materials and Methods.
Flow Cytometry. For apoptosis assays, cells were stained with allophycocyanin
(APC)–anti-AnnexinV and DAPI. For cell cycle analysis, cells were fixed in 70%
(vol/vol) EtOH, and treated with RNase A (19101; Qiagen) and DAPI. Detailed
protocol and antibody information is provided in SI Materials and Methods.
Bone Marrow Transplantation. The detailed protocol is provided in SI Mate-
rials and Methods. Briefly, for primary leukemia assays, freshly transduced
cells were injected by tail vein in cohorts of lethally irradiated ∼8-wk-old
female C57BL/6 mice. At 2 wk, mice were treated with biweekly i.p. injec-
tions of OHT (200 mg/kg, T5648; Sigma) or corn oil. For secondary leukemia
assays, spleen cells harvested from primary leukemic mice in the corn oil-
treated cohort were injected by tail vein in cohorts of sublethally irradiated
∼8-wk-old female C57BL/6 mice. After 5 d, mice were treated for 5 consec-
utive days with i.p. injections of OHT (200 mg/kg) or corn oil and continued
on twice-weekly injections.
ChIP. The detailed protocol is provided in SI Materials and Methods. Briefly,
cells fixed with 1% paraformaldehyde were lysed in SDS lysis buffer and
sonicated to produce chromatin shearing below 500 bp. Diluted chromatin
was incubated overnight with antibody. Antibody was captured using Pro-
tein G Dynabeads (Invitrogen) and washed with low-salt, high-salt, lithium
chloride, and Tris/EDTA buffers. Eluted chromatin was reverse–cross-linked
overnight, RNase A-treated, and purified. Primers used in qPCR are listed in
Table S3.
ChIP-Seq and RNA-Seq. ChIP-seq and RNA-seq libraries were generated using
an Illumina ChIP-seq Library Preparation Kit and Illumina TruSeq RNA Sample
Preparation Kit, respectively. Sequencing was performed on an Illumina
HiSeq2000. Data analysis was performed as described in SI Materials and
Methods. ChIP-seq and RNA-seq datasets have been deposited in the Gene
Expression Omnibus database.
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